By Siddhi Mahatole Jan 29 (Reuters) - Medical device maker ResMed on Thursday beat Wall Street estimates for second-quarter ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $279.86, with a ...

Masks and accessories were the standout growth category for Resmed in the second quarter of its fiscal year 2026, with the company reporting a 16% increase in revenue in the United States, Canada and ...

Resmed (NYSE: RMD) shares ticked up before hours today on second-quarter results that came in ahead of the consensus forecast ...

Q2 2026 Management View CEO Michael Farrell opened the call by highlighting "another strong quarter with 11% headline revenue ...

Revenue increased by 11% to $1.4 billion; up 9% on a constant currency basis Gross margin up 320 bps to 61.8%; non-GAAP gross margin up 310 bps ...

ResMed founder Dr. Peter Farrell has received the Horatio Alger Award, recognizing his contributions to respiratory care and ...

Resmed RMD is set to release its second-quarter fiscal 2026 results on Jan. 29, after the closing bell. The renowned sleep health device maker posted adjusted earnings per share (EPS) of $2.55 in the ...

ResMed CEO Mick Farrell has become the first leader from the home care sector to chair the board of directors at AdvaMed, the trade association representing major medtech companies.

For the quarter ended December 31, 2025, ResMed reported adjusted earnings per share of $2.81, exceeding analyst estimates of $2.73. Revenue increased 11% to $1.4 billion, in line with consensus ...

SAN DIEGO (AP) — SAN DIEGO (AP) — ResMed Inc. (RMD) on Thursday reported fiscal second-quarter net income of $392.6 million.

ResMed Inc (RMD) reports robust financial performance with 11% revenue growth and unveils new product launches amidst ...